Vir Biotechnology Files 8-K on Executive and Board Changes

Ticker: VIR · Form: 8-K · Filed: 2024-04-18T00:00:00.000Z

Sentiment: neutral

Topics: executive-changes, board-changes, filing

TL;DR

Vir Bio 8-K: Exec changes, board elections, comp plans filed 4/18 for 4/15.

AI Summary

Vir Biotechnology, Inc. filed an 8-K on April 18, 2024, reporting on events as of April 15, 2024. The filing covers the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements. It also includes other events and financial statements/exhibits.

Why It Matters

This filing indicates potential shifts in leadership and governance at Vir Biotechnology, which could impact the company's strategic direction and operational execution.

Risk Assessment

Risk Level: medium — Changes in directors or officers, especially if numerous or at senior levels, can signal underlying issues or strategic realignments that may affect the company's future performance.

Key Players & Entities

FAQ

Who specifically departed from their roles at Vir Biotechnology?

The filing indicates the 'Departure of Directors or Certain Officers' as an item, but does not name the individuals in the provided text.

Were there any new directors or officers appointed?

Yes, the filing explicitly lists 'Election of Directors' and 'Appointment of Certain Officers' as reported items.

What is the primary business of Vir Biotechnology, Inc.?

Vir Biotechnology, Inc. is in the business of Biological Products (No Diagnostic Substances), SIC code 2836.

When did the events reported in this 8-K filing occur?

The earliest event reported occurred on April 15, 2024.

What is the principal executive office address for Vir Biotechnology?

The principal executive offices are located at 1800 Owens Street, Suite 900, San Francisco, California 94158.

From the Filing

0001193125-24-100072.txt : 20240418 0001193125-24-100072.hdr.sgml : 20240418 20240418084431 ACCESSION NUMBER: 0001193125-24-100072 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240415 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240418 DATE AS OF CHANGE: 20240418 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Vir Biotechnology, Inc. CENTRAL INDEX KEY: 0001706431 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 812730369 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39083 FILM NUMBER: 24852964 BUSINESS ADDRESS: STREET 1: 1800 OWENS STREET STREET 2: SUITE 900 CITY: SAN FRANCISCO STATE: CA ZIP: 94158 BUSINESS PHONE: 415-906-4324 MAIL ADDRESS: STREET 1: 1800 OWENS STREET STREET 2: SUITE 900 CITY: SAN FRANCISCO STATE: CA ZIP: 94158 8-K 1 d824543d8k.htm 8-K 8-K false 0001706431 0001706431 2024-04-15 2024-04-15     UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549     FORM 8-K     CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 15, 2024     Vir Biotechnology, Inc. (Exact name of Registrant as Specified in Its Charter)       Delaware   001-39083   81-2730369 (State or Other Jurisdiction of Incorporation)   (Commission File Number)   (IRS Employer Identification No.) 1800 Owens Street , Suite 900 San Francisco , California     94158 (Address of Principal Executive Offices)     (Zip Code) Registrant’s Telephone Number, Including Area Code: (415) 906-4324 (Former Name or Former Address, if Changed Since Last Report)     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☒ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common stock, $0.0001 par value   VIR   Nasdaq Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company  ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐       Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On April 15, 2024, Sung Lee, Executive Vice President and Chief Financial Officer of Vir Biotechnology, Inc. (the “Company”), informed the Company that he will be stepping down from his role, effective May 3, 2024, to pursue another career opportunity. The Company has initiated a s

View on Read The Filing